Page 3 - Mayo Collaborative News Today

In 2019 the Federal Circuit reached the extraordinary conclusion, in American Axle & Manufacturing, Inc. v. Neapco Holdings LLC, that a patent for a method of making a drive shaft was...

On July 18, 2022, the United States Court of Appeals for the Federal Circuit (“CAFC”) issued a precedential opinion affirming a judgment by the…

On May 23rd, U.S. District Court Judge James V. Selna of the Central District of California granted summary judgement to Defendant Sweegen, Inc. on its motion that Plaintiff Pure Circle...

The faintest glimmer of hope crept over the clouded patent law horizon today, when the Solicitor General provided the government's views to the Supreme Court in an amicus brief in...

(Part 1 of a 4 Part Series) - The application of innovative data driven approaches such as bioinformatics and artificial intelligence to the life science sector has...

Patent protection, regulatory exclusivity and product life cycle management should be at the core of any company’s life science development strategy. A well-integrated strategy will be...

Finnegan attorneys Paul Browning, Christopher Johns, Sara Leiman and Yelena Morozova explain some of the differences between patent-eligibility standards in the U.S. and those in other parts of the world.

To embed, copy and paste the code into your website or blog: C. R. Bard Inc. and Bard Peripheral Vascular, Inc. (collectively, Bard), and AngioDynamics, Inc., manufactured vascular access ports that were inserted under a patient’s skin to enable medical providers to insert fluid into the patient’s veins without having to initiate a new intravenous line. The Food and Drug Administration (FDA) warned medical providers not to use vascular access ports for power injection unless the ports were ...